Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00795678 · ClinicalTrials.gov registry record
Chemotherapeutic Agents in Brain/Breast
A clinical trial, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- 10
- Enrollment target
NCT00795678 is a clinical trial that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 10 participants.
The verdict
NCT00795678 has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Studying samples of tumor tissue and blood from patients may help doctors understand how well these drugs can be carried to the brain. PURPOSE: More definitive knowledge of the penetration of chemotherapeutic and other agents into the brain is necessary for the future rational design of drug and drug regimens that target brain metastases. This clinical trial is studying how well capecitabine, cyclophosphamide, doxorubicin, gemcitabine, lapatinib, paclitaxel, trastuzumab, or vinorelbine penetrates brain tumors.
Interventions
- DRUG cyclophosphamide
- DRUG capecitabine
- DRUG doxorubicin hydrochloride
- DRUG gemcitabine hydrochloride
- DRUG lapatinib ditosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00795678
The ClinicalTrials.gov registry entry for NCT00795678 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00795678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00795678 about?
NCT00795678 is a clinical study titled "Chemotherapeutic Agents in Brain/Breast". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as trastuzum...
What is the current status of trial NCT00795678?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2008-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00795678?
The interventions under investigation include: cyclophosphamide (DRUG), capecitabine (DRUG), doxorubicin hydrochloride (DRUG), gemcitabine hydrochloride (DRUG), lapatinib ditosylate (DRUG).
Who is sponsoring clinical trial NCT00795678?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.